OBIO
HEALTHCAREOrchestra BioMed Holdings Inc
$4.11+0.10 (+2.49%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving OBIO Today?
No stock-specific AI insight has been generated for OBIO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.20$5.42
$4.11
Fundamentals
Market Cap$246M
P/E Ratio—
EPS$-1.11
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin-1.6%
Debt / Equity—
Trading
Volume446K
Avg Volume (10D)—
Shares Outstanding59.9M
OBIO News
21 articles- Ligand (LGND) Completes $15M Investment in Orchestra BioMedGuruFocus·May 8, 2026
- Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 7, 2026
- TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 6, 2026
- Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing AgreementYahoo Finance·May 6, 2026
- Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing AgreementYahoo Finance·May 6, 2026
- FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM TherapyYahoo Finance·Apr 30, 2026
- NovoCure (NVCR) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·Apr 30, 2026
- Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026Yahoo Finance·Apr 23, 2026
- Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue EstimatesYahoo Finance·Mar 12, 2026
- Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business UpdateYahoo Finance·Mar 12, 2026
- Codexis (CDXS) Beats Q4 Earnings and Revenue EstimatesYahoo Finance·Mar 11, 2026
- Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRTYahoo Finance·Mar 3, 2026
- Orchestra BioMed to Participate in Upcoming Institutional Investor ConferencesYahoo Finance·Feb 19, 2026
- Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Feb 13, 2026
- Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) largest shareholders are retail investors with 41% ownership, institutions own 17%Yahoo Finance·Jan 22, 2026
- Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by HaemoneticsYahoo Finance·Jan 12, 2026
- TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular ProgramsYahoo Finance·Dec 31, 2025
- Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired StockYahoo Finance·Dec 12, 2025
- Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI MeetingYahoo Finance·Dec 8, 2025
- Analyst Confidence in Orchestra BioMed Holdings (OBIO) High Amid Key Clinical and Strategic AdvancementsYahoo Finance·Nov 29, 2025
- Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue EstimatesYahoo Finance·Nov 10, 2025
All 21 articles loaded
Price Data
Open$4.06
Previous Close$4.01
Day High$4.06
Day Low$3.94
52 Week High$5.42
52 Week Low$2.20
52-Week Range
$2.20$5.42
$4.11
Fundamentals
Market Cap$246M
P/E Ratio—
EPS$-1.11
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin-1.6%
Debt / Equity—
Trading
Volume446K
Avg Volume (10D)—
Shares Outstanding59.9M
About Orchestra BioMed Holdings Inc
Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases. The company is headquartered in New Hope, Pennsylvania.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—